The results of the phase III trial showed that treatment with prasugrel was associated with a significant reduction in the composite primary efficacy endpoint as well as in MI, urgent target vessel revascularisation (TVR), and stent thrombosis.
-
Diagram of the heart. -
A section of an artery showing the formation of an atherosclerotic plaque. -
Diagrammatic representation of clot formation showing platelets and... -
The results of the phase III trial showed that treatment with prasugrel was... -
The results of the phase III trial showed that treatment with prasugrel was...
